$ICCM News

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

IceCure Medical Completes Treatment Of First Patient In Its Post-Marketing Study Evaluating ProSense Cryoablation For Local Treatment Of Low-Risk Breast Cancer

IceCure enrols initial patients for ProSense cryoablation trial in US

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026

IceCure Medical Announces Presentations, Posters And Physician Workshops On Its ProSense Breast Cancer Cryoablation At The European Society Of Breast Imaging Annual Scientific Meeting

IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site

IceCure Medical Adds Legacy Health In Portland, Oregon, As New U.S. Clinical Site For Its Post-Marketing ChoICE Study Evaluating Prosense Cryoablation For Treatment Of Low-Risk Breast Cancer

Full Transcript: Icecure Medical Q2 2026 Earnings Call

IceCure Medical Receives Regulatory Approval to Market ProSense® in China

IceCure Medical Receives Approval From China's National Medical Products Administration For Its ProSense System, Associated Cryoprobes

IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

IceCure Medical Inks Distribution Agreement With Scovas Medical To Distribute IceCure's ProSense Cryoablation Systems In Netherlands

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical Says JHM-IRB Of West Cancer Center & Research Institute In Germantown, Tennessee, Approves Post-Marketing Study For ProSense Cryoablation In Local Treatment Of Low-Risk Breast Cancer

Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% as US ...

IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript

IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation

IceCure Medical Highlights Peer‑Reviewed Publications Reinforcing Cryoablation’s Growing Clinical Role In Breast Cancer Treatment De‑Escalation, Including FDA Authorization Of ProSense, Updated ASBrS Guidelines, And Positive ICE3 5‑Yr Outcomes

IceCure Medical Ltd Q2 2026 Earnings Call Summary